$20m-$39.9m

Boehringer Ingelheim Venture Fund co-led a series A round set to drive clinical work on UC Berkeley-founded Actym Therapeutics' immunotherapy pipeline.

JHU-founded restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.

CAS Shanghai Institutes for Biological Sciences spinout Aptbio secured funding to enhance its mass spectrometry drug screening business.

The Parkinson's disease therapy developer completed a series A round featuring QB3-aligned Mission Bay Capital.

Dumac contributed to a round that took the total raised by the cancer screening system developer past the $130m mark.

EPFL spinout Lunaphore has received $2m in a series C extension provided by Swiss Entrepreneurs Fund, adding to an initial $23.6m tranche led by PHC Holdings three months ago.

Tel Aviv University announces $20m commercialisation fund with Tata Industries.

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.

Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.